Skip to content
orbyd

Dossier · CNTA · Dormant

CNTA · Centessa Pharmaceuticals plc · Stock research

LOW Earnings inflection Catalyst · m-and-a-special-situations precision-biotech-therapeutics

Last analysed ·

Current thesis

Resolved special situation: Lilly closed its $38.00 cash plus up-to-$9.00 non-transferable CVR scheme on 2026-06-24 after the 2026-06-22 High Court sanction; last Nasdaq ADS trade was 2026-06-23 and shares have delisted and are deregistering. No US-listed equity remains to trade and no leg exists above the cash.

Invalidation trigger

A daily close below $38.00 cannot print: the ADSs delisted from Nasdaq on 2026-06-24 at the $38.00 cash floor, so the situation is terminal no US-listed equity remains and the only residual, the non-transferable up-to-$9.00 CVR, does not trade.

Thesis status

Open commitment catalyst 27d agoscored if the trigger above fires How this is scored →

Latest analysis and events for CNTA —

As of 2026-07-12, orbyd's latest analysis for Centessa Pharmaceuticals plc (CNTA): Resolved special situation: Lilly closed its $38.00 cash plus up-to-$9.00 non-transferable CVR scheme on 2026-06-24 after the 2026-06-22 High Court sanction; last Nasdaq ADS trade was 2026-06-23 and shares have delisted and are deregistering. No US-listed equity remains to trade and no leg exists above the cash.

Invalidation trigger: A daily close below $38.00 cannot print: the ADSs delisted from Nasdaq on 2026-06-24 at the $38.00 cash floor, so the situation is terminal no US-listed equity remains and the only residual, the non-transferable up-to-$9.00 CVR, does not trade.

Most recent dated event on file: — catalyst 27d ago.

Current Thesis

The special situation has fully resolved and the equity has left the market. On 2026-03-31 Eli Lilly agreed to acquire Centessa via a UK scheme of arrangement for $38.00 cash per share plus one non-transferable CVR worth up to $9.00 (~$7.8B, ~40% premium, +45% on the announcement print). Shareholders approved the scheme on 2026-06-12; the High Court of Justice of England and Wales sanctioned it on 2026-06-22; the last day of ADS trading on Nasdaq was 2026-06-23; the scheme became effective on 2026-06-24 when the court order was delivered to the Registrar of Companies.

Bullish and bearish views on Centessa Pharmaceuticals plc

The model's bull view on Centessa Pharmaceuticals plc (CNTA), in brief: Deal closed at the full cash number: the $38.00 cash cleared without financing, exchange-ratio, or antitrust hold-up; the 2026-06-22 court sanction removed the last condition and the 2026-06-24 effective date locked the consideration. The bear view: No tradable instrument remains: last ADS trade was 2026-06-23; shares delisted 2026-06-24 and are deregistering with the SEC. Both cases follow in full.

Bull Case

  • Deal closed at the full cash number: the $38.00 cash cleared without financing, exchange-ratio, or antitrust hold-up; the 2026-06-22 court sanction removed the last condition and the 2026-06-24 effective date locked the consideration.
  • CVR keeps orexin optionality alive for record holders: the up-to-$9.00 CVR pays on ORX750 development/regulatory milestones (Ph2 NT1 topline guided H2 2026), so a positive readout still pays to the CVR, not to any traded share.
  • Clean strategic logic validated the exit multiple: Lilly's sleep/neuro build ("Lilly completes acquisition… to advance treatments for sleep-wake disorders", 2026-06-24 PRNewswire) gave a specialist orexin asset a strategic buyer, the outcome a catalyst-driven biotech aims for.
  • Institutional base took the deal: the 2026-06-12 vote confirmed the Samlyn / Bain / Perceptive holder set supported the scheme rather than holding out, so there was no drawn-out contest or re-cut risk.

Bear Case

  • No tradable instrument remains: last ADS trade was 2026-06-23; shares delisted 2026-06-24 and are deregistering with the SEC. There is nothing to buy, ride, or stop out of.
  • Narrative was monetized on day one: the entire move was the +45% announcement print on 2026-03-31. Once pinned at the $38 cash, the equity carried no second leg the orexin story converted into a fixed claim.
  • The CVR is non-transferable and binary: common holders received no liquid exposure to the ORX750 Ph2/Ph3 outcome; the milestone payment is contingent, illiquid, and cannot be traded ahead of the H2 2026 data.
  • Sell-side moved to the deal price and stayed there: Needham the mechanical post-M&A reset to cash-plus-a-thin-CVR mark, now moot with the tape gone.

Setup & Price Structure

  • Narrative state: DEAD. Price discovery ended on the 2026-03-31 announcement; the ADSs traded as a deal-pinned instrument from then until the final 2026-06-23 session, then delisted.
  • Levels (historical framing): $38.00 cash was the anchor; PTs of $40–42 (Leerink $40, Wells Fargo $42) reflected $38 cash plus a few dollars of risk-adjusted CVR value. Those marks are now closed with the equity.
  • No technical read applies: a delisted stock has no 20-EMA, no breakout to retest, no chart. The pre-bid ~$27–28 base was the only downside level that ever mattered, and the deal-break tail that would have exposed it never materialized.

Catalyst Calendar (next 30 days)

  • ORX750 Ph2 NT1 topline guided H2 2026 (est., date not set): relevant only to the non-transferable CVR, not to any traded security, and outside the 30-day window.
  • Takeda TAK-861 orexin Ph3 readouts 2026–2027 (est.): a class cross-read for the orexin franchise Lilly now owns, not a Centessa-specific catalyst.

Elapsed catalysts

  • None for the equity. The scheme closed 2026-06-24; there is no earnings print, vote, or listing event ahead the company is private under Lilly. _(passed 25d ago)_

What Would Change Our Mind

  • The situation is terminal; nothing re-opens a Centessa trade. Shares delisted 2026-06-24 at the $38.00 cash floor, so there is no US-listed equity to re-rate.
  • The only path to residual value is the up-to-$9.00 CVR on ORX750 milestones, which is non-transferable and does not trade it cannot be expressed as a position.
  • Remove from the active momentum watchlist: no earnings-blackout logic, no re-entry setup, no forward catalyst attaches to a tradable Centessa security.

Correlation Notes

  • Orexin franchise (Lilly-owned now): Takeda (TAK-861), Alkermes (ALKS-2680/samelisant), and Harmony Biosciences are the remaining public orexin/narcolepsy reads; a positive TAK-861 Ph3 validates the class Lilly bought, a differentiation miss cuts the other way.
  • Biotech M&A regime: closed inside the same 2026-03-31 buyout cluster as Apellis/Biogen ($41/share); the tape confirms large-cap pharma paying ~40% premiums for de-risked neuro/rare-disease assets, a backdrop for other single-asset small-caps rather than for Centessa itself.
  • Eli Lilly (LLY): Centessa is now a line item inside Lilly's neuroscience pipeline; any residual signal flows to LLY and to the CVR, not to a CNTA quote.

Notes

  • Earnings blackout: no new adds in 3 trading days prior to Q1 2026 print (est. 2026-05-07 to 2026-05-14).
  • Archetype: Binary Catalyst institutional holder base (Samlyn/Bain/Perceptive)
  • NOT a retail squeeze; do not apply a6 tight 1% cap.
  • WF downgrade 2026-04-20 is the mainstream-catchup tell narrative state flipped ACCELERATING → MATURING; size smaller on fresh entries.
  • Ph2 ORX750 topline NT1 guided H2 2026 no binary data print in next 30d; 30d risk is headline + earnings only.
  • DILI (liver enzyme) in any 8-K = instant exit
  • no hesitation this is the category-killer risk for OX2R agonists per Takeda's danavorexton history.
  • Takeda TAK-861 Ph3 readouts 2026–2027 any print is cross-read for CNTA (validation positive
  • differentiation risk negative).
  • Eli Lilly definitive acquisition announced 2026-03-31: ~$6.3B upfront cash + up to $1.5B CVR (~$7.8–8B total, ~40% premium). This is a CLOSED deal not a momentum vehicle.
  • Analyst downgrade cluster (Needham/Wolfe/Guggenheim/Leerink/Wells Fargo, 2026-03-31→04-20) is the standard post-M&A move-to-neutral PTs mechanically reset to the ~$40 deal price. NOT a thesis-break signal.
  • DEAD for narrative-momentum: stock pinned near ~$40 cash value; only residual return is the merger-arb spread to close (~few% — not this playbook's edge).
  • Deal-break tail (termination 8-K / FTC second request) gaps toward pre-bid ~$28–30. Topping bid is the low-probability upside. Asymmetric: ~3–5% up vs ~30% down.
  • Prior ORX750 catalyst-calendar thesis is OBSOLETE: the H2 2026 Ph2 NT1 readout no longer drives the equity it now drives a (illiquid/contingent) CVR. The 2026-05-08 catalyst date is void.
  • Remove from active momentum watchlist once the deal closes / shares delist (expected ~Q3 2026, est.). No earnings blackout logic applies company is being acquired.
  • Deal closing imminent: UK scheme of arrangement passed shareholder vote 2026-06-12; Court Sanction Hearing 2026-06-22 (Royal Courts of Justice, London); effective/close expected before open ~2026-06-24; ADSs then delist from Nasdaq + deregister with SEC. Remove from active universe on delisting.
  • Consideration is $38.00 cash + up to $9.00 non-transferable CVR per share (~$47 headline, ~$7.8B, ~40% premium). Prior '~$40 cash' framing was imprecise cash is $38.00; the $2-4 above it is risk-adjusted CVR value embedded in the $40-42 sell-side PTs.
  • Structure is an English-law scheme of arrangement via Lilly sub LDH XV Corporation, NOT a US tender offer court sanction (2026-06-22) is the operative final gate, not an FTC/HSR clearance.
  • DEAD for narrative-momentum: spread to the $38 cash is closed; CVR is non-transferable/illiquid. No tradable equity catalyst remains above a fixed bid.
  • Original ORX750 H2 2026 Ph2 NT1 readout now drives the CVR payout, not the common; the prior 2026-05-08 catalyst date is void.
  • DILI (liver-enzyme) signal in any orexin-agonist 8-K = category-killer risk for OX2R agonists per Takeda danavorexton history relevant now to the CVR milestone and class read-through, not the equity post-close.
  • Institutional holder base (Samlyn/Bain/Perceptive), not a retail squeeze do not apply a tight retail-cap; this is a completed-deal arb, near-zero correlation to XBI while pinned.
  • TERMINAL: Lilly acquisition closed 2026-06-24; ADSs delisted from Nasdaq (last trade 2026-06-23), deregistering with SEC. No tradable US-listed equity remains remove from active momentum watchlist.
  • Deal economics: $38.00 cash + up to $9.00 non-transferable CVR (~$7.8B, ~40% premium). CVR pays on ORX750 milestones (Ph2 NT1 topline guided H2 2026) but does not trade cannot be expressed as a position.
  • Acquirer vehicle: LDH XV Corporation (Lilly subsidiary). ATM program and Oxford Finance loan terminated at close. Centessa now wholly owned by Lilly.
  • Analyst downgrade cluster (Needham/Wolfe 2026-03-31, Leerink $40 04-01, Guggenheim 04-02, Wells Fargo $42 04-20) was the standard post-M&A reset to deal price, not a thesis-break signal now moot with the equity delisted.
  • No earnings-blackout logic applies going forward: the company is private under Lilly. Any future orexin cross-read (Takeda TAK-861 Ph3, Alkermes ALKS-2680) flows to those names or to LLY, not to CNTA.
  • Ignore crypto-blog headlines claiming a '183% surge' at close reputable filings (PRNewswire/GlobeNewswire/StockTitan/TipRanks) confirm a pinned $38 cash close, not a rally.

Related · shared themes

MRCY

Mercury Systems Inc

Defense-electronics turnaround re-rating inside an accelerating modernization tape: Q3 FY26 (2026-05-06) printed record bookings $348M (+73.7% YoY), 1.48 book-to-bill, record ~$1.6B backlog and +46% EBITDA, with FCF guided positive. But the stock just reversed ~16% off its $128.45 ATH; the ~2026-08-10 Q4/full-year print is the next binary.

MEDIUM

SIMO

Silicon Motion Technology Corporation

NAND-controller toll-booth on the steepest flash shortage in ~15 years: TrendForce H1 2026 contract +>100% cumulative, H2 still rising with no capacity adds. Q1 record +105% YoY, sell-side chasing to $400/$450. Fundamental leg ACCELERATING, but the tape is digesting a 4x into insider selling the 2026-07-29 Q2 print is the next binary.

MEDIUM

XPO

XPO, Inc.

Freight-cycle upturn is the accelerating narrative: LTL volume and contract pricing re-accelerating after a multi-year trucking recession, with SAIA May tonnage +8.4% confirming the cluster. XPO layers operating-ratio self-help (Q1 LTL OR 83.9%, -200bps YoY) on top. The 2026-07-30 Q2 print is the binary that validates or breaks the "comfortably ahead" yield guide.

MEDIUM

IRDM

Iridium Communications Inc

Narrative-momentum thesis is closed: Rocket Lab agreed 2026-06-29 to acquire Iridium for ~$54/share ($27 cash + a calculated ratio of RKLB stock), EV ~$8B. IRDM now trades as merger-arb spread to ~$54 plus embedded RKLB beta not on NTN Direct or spectrum. Morgan Stanley's PT-to-$54 (2026-06-30) confirms the Street marks it to the deal. Upside is capped at terms; the live binary is deal close vs. break on a 6–12 month regulatory clock.

LOW